Complications and Occurrence of Exacerbations in Patients with Myasthenia Gravis Treated with Oral Corticosteroids
-
By
-
Zhiwen Liu
-
Louis Jackson
-
Jacqueline Pesa
-
Alicia K. Campbell
-
Zia Choudhry
-
Nizar Souayah
-
July 8, 2026
-
Clinical Scorecard: Complications and Frequency of Exacerbations in Myasthenia Gravis Patients Undergoing Oral Corticosteroid Therapy
At a Glance
| Category | Detail |
|---|
| Condition | Myasthenia Gravis |
| Key Mechanisms | Autoantibody-driven disease affecting neuromuscular junctions. |
| Target Population | US patients with myasthenia gravis undergoing oral corticosteroid therapy. |
| Care Setting | Real-world clinical practice. |
Key Highlights
- Patients on oral corticosteroids experienced higher rates of complications such as infection and osteoporosis.
- Exacerbations of myasthenia gravis were more frequent in patients with continuous oral corticosteroid exposure.
- 10-20% of patients do not achieve adequate treatment response with standard therapies.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of myasthenia gravis should be confirmed with appropriate clinical and laboratory criteria.
Management
- Standard-of-care therapies include acetylcholinesterase inhibitors, oral corticosteroids, and non-steroidal immunosuppressive treatments.
Monitoring & Follow-up
- Patients on oral corticosteroids should be monitored for complications and exacerbations.
Risks
- Long-term oral corticosteroid use is associated with increased risk of complications.
Patient & Prescribing Data
Adults aged ≥ 18 years with a diagnosis of myasthenia gravis.
Corticosteroids remain a central component of treatment despite associated risks.
Clinical Best Practices
- Consider alternative treatment options for patients with uncontrolled symptoms.
- Regularly assess patients for signs of corticosteroid-related complications.
Related Resources & Content
